STING1 and neoplasm: reported that engineered peptide‐expressed biomimetic CM‐encapsulated STING agonists can significantly enhance type I interferon (IFN) secretion in dendritic cells and inhibit PD‐1 unresponsive tumor growth without causing obvious side effects.[23] Furthermore, Wang et al.